笔丑辞蝉辫丑辞-滨狈笔笔尝1(罢测谤1135)抗体特异性结合抗原：抗体本身不能直接溶解或杀伤带有特异抗原的靶细胞，通常需要补体或吞噬细胞等共同发挥效应以**病原微生物或导致病理损伤。然而，抗体可通过与病毒或**的特异性结合，直接发挥中和病毒的作用。
产物编号xy- 3399R
英文名称笔丑辞蝉辫丑辞-滨狈笔笔尝1(罢测谤1135)
中文名称磷酸化肌醇聚磷酸盐磷酸酶样蛋白1抗体
别 名INPPL1(Phospho Tyr1135); INPPL1(Phospho Y1135); INPPL1(Phospho-Tyr1135); 5-trisphosphate 5-phosphatase 2; 51C protein; EC 3.1.3.n1; inositol polyphosphate phosphatase like 1; Inositol polyphosphate phosphatase like protein 1; Inositol polyphosphate phosphatase-like protein 1; INPPL-1; INPPL1; Phosphatidylinositol 3; Phosphatidylinositol 3,4,5 trisphosphate 5 phosphatase 2; Protein 51C; SH2 domain containing inositol 5' phosphatase 2; SH2 domain-containing inositol 5''-phosphatase 2; SH2 domain-containing inositol phosphatase 2; SHIP-2; SHIP2; SHIP2_HUMAN.
说 明 书100ul
产物类型磷酸化抗体
研究领域肿瘤 心血管 **学 神经生物学 信号转导 生长因子和** 激酶和磷酸酶 细胞骨架 新陈代谢 细胞外基质
抗体来源搁补产产颈迟
克隆类型笔辞濒测肠濒辞苍补濒
笔丑辞蝉辫丑辞-滨狈笔笔尝1(罢测谤1135)抗体交叉反应 Human, Mouse, Dog, Cow, Horse, Rabbit,
产物应用WB=1:500-2000 ELISA=1:500-1000 IHC-P=1:400-800 IHC-F=1:400-800 IF=1:100-500 （石蜡切片需做抗原修复）
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
分 子 量139kDa
细胞定位细胞浆 细胞膜
性 状Lyophilized or Liquid
浓 度1mg/1ml
免 疫 原KLH conjugated Synthesised phosphopeptide derived from human SHIP2 around the phosphorylation site of Tyr1135:VD(p-Y)AP
亚 型IgG
纯化方法affinity purified by Protein A
储 存 液0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
笔丑辞蝉辫丑辞-滨狈笔笔尝1(罢测谤1135)抗体保存条件Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
PubMedPubMed
产物介绍产补肠办驳谤辞耻苍诲:
The steady state of protein tyrosyl phosphorylation in cells is regulated by the opposing action of tyrosine kinases and protein tyrosine phosphatases (PTPs). Several groups have independently identified a non transmembrane PTP, designated SHPTP1 (also known as PTP1C, HCP and SHP), which is primarily expressed in hematopoietic cells and characterized by the presence of two SH2 domains N terminal to the PTP domain. A second and much more widely expressed PTP with SH2 domains, SHPTP2 (also designated PTP1D and Syp), has been identified. SHP2 is a protein tyrosine phosphatase that is widely expressed and plays a regulatory role in various cell signaling events that are important for many cell functions, such as mitogenic activation, metabolic control, transcription regulation, and cell migration.
Function:
Phosphatidylinositol (PtdIns) phosphatase that specifically hydrolyzes the 5-phosphate of phosphatidylinositol-3,4,5-trisphosphate (PtdIns(3,4,5)P3) to produce PtdIns(3,4)P2, thereby negatively regulating the PI3K (phosphoinositide 3-kinase) pathways. Plays a central role in regulation of PI3K-dependent insulin signaling, although the precise molecular mechanisms and signaling pathways remain unclear. While overexpression reduces both insulin-stimulated MAP kinase and Akt activation, its absence does not affect insulin signaling or GLUT4 trafficking. Confers resistance to dietary obesity. May act by regulating AKT2, but not AKT1, phosphorylation at the plasma membrane. Part of a signaling pathway that regulates actin cytoskeleton remodeling. Required for the maintenance and dynamic remodeling of actin structures as well as in endocytosis, having a major impact on ligand-induced EGFR internalization and degradation. Participates in regulation of cortical and submembraneous actin by hydrolyzing PtdIns(3,4,5)P3 thereby regulating membrane ruffling. Regulates cell adhesion and cell spreading. Required for HGF-mediated lamellipodium formation, cell scattering and spreading. Acts as a negative regulator of EPHA2 receptor endocytosis by inhibiting via PI3K-dependent Rac1 activation. Acts as a regulator of neuritogenesis by regulating PtdIns(3,4,5)P3 level and is required to form an initial protrusive pattern, and later, maintain proper neurite outgrowth. Acts as a negative regulator of the FC-gamma-RIIA receptor (FCGR2A). Mediates signaling from the FC-gamma-RIIB receptor (FCGR2B), playing a central role in terminating signal transduction from activating immune/hematopoietic cell receptor systems. Involved in EGF signaling pathway. Upon stimulation by EGF, it is recruited by EGFR and dephosphorylates PtdIns(3,4,5)P3. Plays a negative role in regulating the PI3K-PKB pathway, possibly by inhibiting PKB activity. Down-regulates Fc-gamma-R-mediated phagocytosis in macrophages independently of INPP5D/SHIP1. In macrophages, down-regulates NF-kappa-B-dependent gene transcription by regulating macrophage colony-stimulating factor (M-CSF)-induced signaling. May also hydrolyze PtdIns(1,3,4,5)P4, and could thus affect the levels of the higher inositol polyphosphates like InsP6
Subunit:
Interacts with tyrosine phosphorylated form of SHC1, Interacts with EGFR. Upon stimulation by the EGF signaling pathway, it forms a complex with SHC1 and EGFR. Interacts with cytoskeletal protein SORBS3/vinexin, promoting its localization to the periphery of cells. Forms a complex with filamin (FLNA or FLNB), actin, GPIb (GP1BA or GP1BB) that regulates cortical and submembraneous actin. Interacts with c-Met/MET, when c-Met/MET is phosphorylated on 'Tyr-1356'. Interacts with p130Cas/BCAR1. Interacts with CENTD3/ARAP3 via its SAM domain. Interacts with c-Cbl/CBL and CAP/SORBS1. Interacts with activated EPHA2 receptor. Interacts with receptors FCGR2A and FCGR2B. Interacts with tyrosine kinases ABL1 and TEC. Interacts with CSF1R.
Subcellular Location:
Cytoplasm, cytosol. Cytoplasm, cytoskeleton, actin patch. Membrane; Peripheral membrane protein.
Tissue Specificity:
Widely expressed, most prominently in skeletal muscle, heart and brain. Present in platelets. Expressed in transformed myeloid cells and in primary macrophages, but not in peripheral blood monocytes.
Post-translational modifications:
Tyrosine phosphorylated by the members of the SRC family after exposure to a diverse array of extracellular stimuli such as insulin, growth factors such as EGF or PDGF, chemokines, integrin ligands and hypertonic and oxidative stress. May be phosphorylated upon IgG receptor FCGR2B-binding. Phosphorylated at Tyr-986 following cell attachment and spreading. Phosphorylated at Tyr-1162 following EGF signaling pathway stimulation. Phosphorylated at Thr-958 in response to PDGF.
DISEASE:
Defects in INPPL1 may be a cause of susceptibility to type 2 diabetes mellitus non-insulin dependent (NIDDM) [MIM:125853].
Note=Genetic variations in INPPL1 may be a cause of susceptibility to metabolic syndrome. Metabolic syndrome is characterized by diabetes, insulin resistance, hypertension, and hypertriglyceridemia is absent.
Similarity:
Belongs to the inositol 1,4,5-trisphosphate 5-phosphatase family.
Contains 1 SAM (sterile alpha motif) domain.
Contains 1 SH2 domain.
SWISS:
O15357
Gene ID:
3636
笔丑辞蝉辫丑辞-滨狈笔笔尝1(罢测谤1135)抗体（antibody,
Ab）是由效应B细胞（效应**B细胞）分泌，机体用于抵御外来物质，如病毒，**等抗原，结构呈“驰”字型的球状蛋白质，仅仅存在于脊椎动物的血液和B**细胞膜表面。凡是能够跟抗体结合的物质，均被称作抗原，因此对于抗抗体（能够结合抗体的抗体）来说，抗体本身也是一种抗原物质。
笔丑辞蝉辫丑辞-滨狈笔笔尝1(罢测谤1135)抗体普通抗体重链和轻链的结构
重链结构：普通的**球蛋白具有2条重链（H链），分子量约为50kD,有μ、δ、γ、ε和α五种重链亚型，对应的**球蛋白名称分别为IgM、IgG、IgA、IgD和IgE。
轻链结构： 普通**球蛋白具有2条轻链（L链），分子质量约25kDa，有κ链和λ链两种亚型，这两种轻链决定了Ig的亚型类别（IgG1，IgG2，IgG3，IgG4）。一个天然的Ig分子两条轻链总是相同的，但在同一个体内可存在分别带有κ或λ链的抗体分子。不同种属生物体内两型轻链的比例不同，正常人血清**球蛋白κ链：λ链约为2：1，而在小鼠的比例为20：1。
2.2抗体Fab段和Fc段
滨驳骋经木瓜蛋白酶酶切后裂解为2个完全相同的Fab段和1个Fc段,每个Fab段都为单价,可与抗原结合但不会再发生凝集反应；经胃蛋白酶酶切后裂解为1个完整F(ab)2片段和碎片化的Fc片段,F(ab’)2片段为双价,可同时结合两个抗原表位。Fab段为抗原结合片段（fragment of antigen binding，Fab），相当于抗体分子的两个臂，由一个完整的轻链和重链的VH和CH1结构域组成。Fc段为可结晶段（fragment crystallizable，Fc）相当于Ig的CH2和CH3结构域，是Ig与效应分子或者细胞相互作用的部位。Fab段包含完整的可变区，以及恒定区的CH1区域。Fc段仅指Ig恒定区CH2和CH3的区域，相当于Y字结构下面那一部分。
合格 Calpain 2 钙激活的中性蛋白酶2抗体
合格 FAM49B FAM49B蛋白抗体
合格 FAM55A FAM55A蛋白抗体
合格 FAM55C FAM55C蛋白抗体
合格 FAM58A FAM58A蛋白抗体
合格 Gamma-Adaptin 衔接蛋白γ/γ-Adaptin抗体
合格 FAM73A FAM73A蛋白抗体
合格 FAM73B FAM73B蛋白抗体
合格 FAM83A FAM83A蛋白抗体
合格 合格 FAM83E FAM83E蛋白抗体
合格 FAM90A1 FAM90A1蛋白抗体
合格 合格 FAM98C FAM98C蛋白抗体
合格 FARSLB FARSLB蛋白抗体
合格 Phospho-MAP2 (Thr1613/1619) 磷酸化微管相关蛋白2(Thr1613/1619)抗体
合格 FBXO22 FBXO22蛋白抗体
合格 FBXO44 FBXO44蛋白抗体
合格 FBXO46 FBXO46蛋白抗体
合格 合格 FBXW9 FBXW9蛋白抗体
合格 FCF1 FCF1蛋白抗体
合格 FCRL1 CD307a抗体
合格 FcRH2 CD307b抗体
合格 CYP1A1 细胞色素P450 1A1抗体
合格 合格 FDXACB1 FDXACB1蛋白抗体
合格 合格 FGD1 FGD1蛋白抗体
合格 FGD3 FGD3蛋白抗体
合格 CK II alpha 丝/苏氨酸蛋白质激酶II α抗体
合格 FGD5 FGD5蛋白抗体
合格 FKLF FKLF蛋白抗体
合格 FKRP FKRP蛋白抗体
合格 FMO4 肝黄素单加氧酶4抗体
合格 FLJ10357 SOLO蛋白抗体
合格 TTC30A TTC30A蛋白抗体
合格 CK7 细胞角蛋白7抗体
合格 FLJ25006 FLJ25006蛋白抗体
合格 C2orf63 2号染色体开放阅读框63抗体
合格 Cathepsin K 组织蛋白酶K抗体
合格 ZNF778 锌指蛋白778抗体